{"2502.13344": {"publish_time": "2025-02-18", "title": "K-Paths: Reasoning over Graph Paths for Drug Repurposing and Drug Interaction Prediction", "paper_summary": "Drug discovery is a complex and time-intensive process that requires\nidentifying and validating new therapeutic candidates. Computational approaches\nusing large-scale biomedical knowledge graphs (KGs) offer a promising solution\nto accelerate this process. However, extracting meaningful insights from\nlarge-scale KGs remains challenging due to the complexity of graph traversal.\nExisting subgraph-based methods are tailored to graph neural networks (GNNs),\nmaking them incompatible with other models, such as large language models\n(LLMs). We introduce K-Paths, a retrieval framework that extracts structured,\ndiverse, and biologically meaningful paths from KGs. Integrating these paths\nenables LLMs and GNNs to effectively predict unobserved drug-drug and\ndrug-disease interactions. Unlike traditional path-ranking approaches, K-Paths\nretrieves and transforms paths into a structured format that LLMs can directly\nprocess, facilitating explainable reasoning. K-Paths employs a diversity-aware\nadaptation of Yen's algorithm to retrieve the K shortest loopless paths between\nentities in an interaction query, prioritizing biologically relevant and\ndiverse relationships. Our experiments on benchmark datasets show that K-Paths\nimproves the zero-shot performance of Llama 8.1B's F1-score by 12.45 points on\ndrug repurposing and 13.42 points on interaction severity prediction. We also\nshow that Llama 70B achieves F1-score gains of 6.18 and 8.46 points,\nrespectively. K-Paths also improves the supervised training efficiency of\nEmerGNN, a state-of-the-art GNN, by reducing KG size by 90% while maintaining\nstrong predictive performance. Beyond its scalability and efficiency, K-Paths\nuniquely bridges the gap between KGs and LLMs, providing explainable rationales\nfor predicted interactions. These capabilities show that K-Paths is a valuable\ntool for efficient data-driven drug discovery.", "paper_summary_zh": "<paragraph>\u85e5\u7269\u767c\u73fe\u662f\u4e00\u500b\u8907\u96dc\u4e14\u8017\u6642\u7684\u904e\u7a0b\uff0c\u9700\u8981\u8b58\u5225\u548c\u9a57\u8b49\u65b0\u7684\u6cbb\u7642\u5019\u9078\u85e5\u7269\u3002\u4f7f\u7528\u5927\u578b\u751f\u7269\u91ab\u5b78\u77e5\u8b58\u5716\u8b5c (KG) \u7684\u8a08\u7b97\u65b9\u6cd5\u63d0\u4f9b\u4e86\u4e00\u500b\u6709\u5e0c\u671b\u7684\u89e3\u6c7a\u65b9\u6848\u4f86\u52a0\u901f\u9019\u500b\u904e\u7a0b\u3002\u7136\u800c\uff0c\u7531\u65bc\u5716\u5f62\u904d\u6b77\u7684\u8907\u96dc\u6027\uff0c\u5f9e\u5927\u578b KG \u4e2d\u63d0\u53d6\u6709\u610f\u7fa9\u7684\u898b\u89e3\u4ecd\u7136\u5177\u6709\u6311\u6230\u6027\u3002\u73fe\u6709\u7684\u5b50\u5716\u65b9\u6cd5\u662f\u91dd\u5c0d\u5716\u795e\u7d93\u7db2\u8def (GNN) \u91cf\u8eab\u6253\u9020\u7684\uff0c\u9019\u4f7f\u5f97\u5b83\u5011\u8207\u5176\u4ed6\u6a21\u578b\uff08\u4f8b\u5982\u5927\u578b\u8a9e\u8a00\u6a21\u578b (LLM)\uff09\u4e0d\u517c\u5bb9\u3002\u6211\u5011\u4ecb\u7d39\u4e86 K-Paths\uff0c\u9019\u662f\u4e00\u500b\u6aa2\u7d22\u6846\u67b6\uff0c\u5b83\u5f9e KG \u4e2d\u63d0\u53d6\u7d50\u69cb\u5316\u3001\u591a\u6a23\u5316\u4e14\u5177\u6709\u751f\u7269\u610f\u7fa9\u7684\u8def\u5f91\u3002\u6574\u5408\u9019\u4e9b\u8def\u5f91\u4f7f LLM \u548c GNN \u80fd\u5920\u6709\u6548\u9810\u6e2c\u672a\u89c0\u5bdf\u5230\u7684\u85e5\u7269-\u85e5\u7269\u548c\u85e5\u7269-\u75be\u75c5\u4ea4\u4e92\u3002\u8207\u50b3\u7d71\u7684\u8def\u5f91\u6392\u5e8f\u65b9\u6cd5\u4e0d\u540c\uff0cK-Paths \u6aa2\u7d22\u8def\u5f91\u4e26\u5c07\u5176\u8f49\u63db\u70ba LLM \u53ef\u4ee5\u76f4\u63a5\u8655\u7406\u7684\u7d50\u69cb\u5316\u683c\u5f0f\uff0c\u5f9e\u800c\u4fc3\u9032\u53ef\u89e3\u91cb\u7684\u63a8\u7406\u3002K-Paths \u63a1\u7528\u4e86 Yen \u6f14\u7b97\u6cd5\u7684\u591a\u6a23\u6027\u611f\u77e5\u9069\u61c9\uff0c\u4ee5\u6aa2\u7d22\u4ea4\u4e92\u67e5\u8a62\u4e2d\u5be6\u9ad4\u4e4b\u9593\u7684 K \u500b\u6700\u77ed\u7121\u74b0\u8def\u5f91\uff0c\u512a\u5148\u8003\u616e\u751f\u7269\u76f8\u95dc\u4e14\u591a\u6a23\u5316\u7684\u95dc\u4fc2\u3002\u6211\u5011\u5728\u57fa\u6e96\u8cc7\u6599\u96c6\u4e0a\u7684\u5be6\u9a57\u8868\u660e\uff0cK-Paths \u5c07 Llama 8.1B \u7684 F1 \u5206\u6578\u5728\u85e5\u7269\u518d\u5229\u7528\u4e0a\u63d0\u9ad8\u4e86 12.45 \u5206\uff0c\u5728\u4ea4\u4e92\u56b4\u91cd\u6027\u9810\u6e2c\u4e0a\u63d0\u9ad8\u4e86 13.42 \u5206\u3002\u6211\u5011\u9084\u8868\u660e\uff0cLlama 70B \u5206\u5225\u7372\u5f97\u4e86 6.18 \u5206\u548c 8.46 \u5206\u7684 F1 \u5206\u6578\u589e\u76ca\u3002K-Paths \u9084\u63d0\u9ad8\u4e86\u6700\u5148\u9032\u7684 GNN EmerGNN \u7684\u76e3\u7763\u8a13\u7df4\u6548\u7387\uff0c\u540c\u6642\u5c07 KG \u5927\u5c0f\u6e1b\u5c11\u4e86 90%\uff0c\u540c\u6642\u4fdd\u6301\u5f37\u5927\u7684\u9810\u6e2c\u6027\u80fd\u3002\u9664\u4e86\u5176\u53ef\u64f4\u5c55\u6027\u548c\u6548\u7387\u4e4b\u5916\uff0cK-Paths \u7368\u7279\u5730\u5f4c\u5408\u4e86 KG \u548c LLM \u4e4b\u9593\u7684\u5dee\u8ddd\uff0c\u70ba\u9810\u6e2c\u7684\u4ea4\u4e92\u63d0\u4f9b\u4e86\u53ef\u89e3\u91cb\u7684\u4f9d\u64da\u3002\u9019\u4e9b\u529f\u80fd\u8868\u660e\uff0cK-Paths \u662f\u7528\u65bc\u9ad8\u6548\u8cc7\u6599\u9a45\u52d5\u85e5\u7269\u767c\u73fe\u7684\u5bf6\u8cb4\u5de5\u5177\u3002</paragraph>", "author": "Tassallah Abdullahi et.al.", "authors": "Tassallah Abdullahi, Ioanna Gemou, Nihal V. Nayak, Ghulam Murtaza, Stephen H. Bach, Carsten Eickhoff, Ritambhara Singh", "id": "2502.13344v1", "paper_url": "http://arxiv.org/abs/2502.13344v1", "repo": "null"}}